Viridian’s lead product candidate, VRDN-001, is a potential best-in-class, IV monoclonal antibody targeting IGF-1R. VRDN-001 acts as a full antagonist of IGF-1R, and based on clinical data to date, has demonstrated robust clinical activity and was generally well-tolerated at Week 6 compared with the currently approved anti-IGF-1R antibody.1
The company is running two global Phase 3 trials, THRIVE (NCT05176639) and THRIVE-2 (NCT06021054), for people living with active and chronic TED, respectively.
1 Conclusions are not based on head-to-head clinical trial results.
VRDN-003 is a potential best-in-class subcutaneous anti-IGF-1R program in development for TED. VRDN-003 has the same binding domain as its parent molecule, VRDN-001, and was engineered to have a longer half-life. VRDN-003 is designed to maintain the clinical response of VRDN-001 IV while significantly increasing patient convenience and potentially improving safety.
The company expects to initiate a pivotal program for VRDN-003 in mid-2024 pending alignment with regulatory authorities.